Chief Technology Officer

Ashley Taylor

Ashley is an experienced biotech executive with 35 years of industry experience, having focused on all aspects of CMC, product strategy, and manufacturing execution for clinical and commercial supply at leading manufacturing organizations. He joins Verdiva Bio having been Chief Technology Officer at Aiolos Bio prior to its sale to GSK in 2024. Directly prior to that, he was Head of Network Strategy for Roche.

Ashley has provided executive CMC leadership at a range of companies, from startups to large pharma. He began his career at Genentech in manufacturing operations, before joining startup Abgenix which was acquired by Amgen where he stayed, ultimately leading Amgen’s Manufacturing Leadership Team. Ashley returned to Roche/Genentech in 2013, leading a variety of functions over the next ten years including External Manufacturing, Technical Product Teams, and South San Francisco Production Operations overseeing a diverse array of clinical and commercial products.

A chemist by training, Ashley holds his degree in Chemistry from the University of California, Berkeley.